Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mapping the Melanoma Plasma Proteome (MPP) using Single-Shot Proteomics and Custom Protein Databases

ABSTRACT: We mapped the Melanoma Plasma Proteome (MPP) of undepleted samples a new strategy for protein identification refered here as Wise MS transfer (WiMT). We were able to identify more than 1,000 protein in undepleted plasma samples which shows a deep coverage of the plasma proteome. The MPP of undeplted samples was well characterized showing a great potential for large-scale screening of melanoma proteomics studies and other neoplastic diseases.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Melanoma

SUBMITTER: Natália Almeida

LAB HEAD: György Marko-Varga

PROVIDER: PXD028709 | Pride | 2021-12-27

REPOSITORIES: pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20200117_PlasmaMM_POOL2_DDA_R1.raw	Raw
	20200117_PlasmaMM_SUD068_DDA_R1.raw	Raw
	20200124_PlasmaMM_POOL2_DDA_R1.raw	Raw
	20200124_PlasmaMM_SUD050_DDA_R1.raw	Raw
	20200131_PlasmaMM_POOL2_DDA_R1_20200202195203.raw	Raw

Items per page:

1 - 5 of 31

Similar Datasets

Affinity capture enrichment versus Affinity depletion: A comparison of strategies for increasing coverage of low abundant human plasma proteins

Project description:present study, we evaluated four small molecule affinity-based probes based on agarose-immobilized benzamidine (ABA), O-Phospho-L-Tyrosine (pTYR), 8-Amino-hexyl-cAMP (cAMP), or 8-Amino-hexyl-ATP (ATP) for their ability to remove high-abundant proteins such as serum albumin from plasma samples thereby enabling the detection of medium-to-low abundant proteins in plasma samples by mass spectrometry-based proteomics. We compared their performance with the commonly used immunodepletion method, the Multi Affinity Removal System Human 14 (MARS14) targeting the top 14 most abundant plasma proteins and also the ProteoMiner protein equalization method by label-free quantitative LC-MSMS analysis. The affinity-based probes demonstrated high reproducibility for low abundant plasma proteins, down to picomol per ml levels, compared to the MARS14 and the Proteominer methods, and also demonstrated a superior removal of the majority of the high abundant plasma proteins. The ABA-based affinity probe and the Proteominer protein equalization method performed superior compared to all other methods in terms of the number of analyzed proteins. All the tested methods were highly reproducible for both high-abundant plasma proteins and low abundant proteins as measured by correlation analysis of six replicate experiments. In conclusion, our results demonstrated that small-molecule based affinity-based probes are excellent alternatives to the commonly used immune-depletion methods for proteomic biomarker discovery studies in plasma.

2020-08-27 | PXD020727 | Pride

miRNA profiling in the plasma of patients with acute myocardial infarction (AMI)

Project description:Studies of miRNA profiling in the plasma of AMI patients with Left ventricular end diastolic volume (LVEDV) increase or LVEDV decrease between discharge and follow-up Venous blood was collected in citrated tubes prior discharge. Plasma was harvested by centrifugation and stored at -80Â°C until assayed. Identical volumes of plasma from the 30 patients of a group (LVEDV increase or LVEDV decrease) were pooled to reach a final volume of 400ÂµL for each group. The two pools were processed conjointly. Total RNA was extracted using miRVana isolation kit (Applied Biosystems), dephosphorylated and labeled using miRNA Complete Labeling and hybridization kit (Agilent). Hybridization was performed on miRNA Human Microarray Release 12.0 slides (Agilent). 4 arrays per pool were hybridized. Scanning was achieved with the Genepix 4000B Scanner (Molecular Devices, Sunnyvale, USA). Raw data were acquired with the Genepix Pro software (Molecular Devices).

2013-05-14 | E-GEOD-34571 | biostudies-arrayexpress

RNA-seq Validation of MicroRNA Expression Signatures for Precision Melanoma Diagnosis and Prognostication

Project description:This study aimed to transition genomic signatures of invasive cutaneous melanoma (MEL38 for diagnosis and MEL12 for prognosis) from Nanostring to a high-throughput RNAseq platform using the gel-free NEXTflex Small RNA Library Prep Kit. We validated against 59 FFPE and 61 plasma samples from patients with melanoma and normal tissue . MEL38 accurately diagnosed invasive melanoma across different sample types and platforms, unaffected by disease stage or data origin. The MEL12 signature significantly stratified patients by survival rates in solid tissues, surpassing previous prognostic models based on DNA, mRNA, or protein analysis, with hazard ratios indicating high risk. In plasma, MEL12 also differentiated survival outcomes. Overall, the study confirms the reliability of MEL38 and MEL12 in predicting melanoma presence and prognosis, demonstrating their superiority and adaptability across specimen types and platforms, marking a substantial advancement in personalized melanoma management.

2024-10-10 | GSE266859 | GEO

Pediatric COVID-19 Human plasma LC-MS

Project description:Analysis of plasma from adult and pediatric COVID-19 patients via untargeted and targeted proteomics reveals activation in complement and coagulation pathways as common elements in both populations

2023-03-06 | PXD040437 | Pride

Proteome of fluid from human ovarian small antral follicles reveals insights in folliculogenesis and oocyte maturation.

Project description:Protein composition of human ovarian follicular fluid (FF) constitutes the microenvironment for oocyte development. Several proteomics studies of FF from pre-ovulatory follicles have revealed insights on oocyte maturation, however, there is a lack of knowledge on changes produced at protein levels in the FF of human small antral follicles (hSAF) related to the upcoming oocyte maturation. Using mass spectrometry-based proteomics, we evaluated the protein composition of FF that surrounds oocytes capable to reach metaphase II (MII) after IVM with the protein profile of FF that surrounds immature oocytes. The samples were collected from small antral follicles (size 6.0 ± 1.5 mm) extracted from six women, from which two or three samples were extracted. The comparison was based on both, a multivariate (sPLS-DA) and univariate analyses (t-test).

2021-09-09 | PXD021338 | Pride

Circulating microRNAs to predict neurological outcome after sudden cardiac arrest

Project description:Studies of miRNA profiling to predict outcome in cardiac arrest patients treated with therapeutic hypothermia (TH) Venous blood was collected in citrated tubes prior discharge. Plasma was harvested by centrifugation and stored at -80Â°C until assayed. Identical volumes of plasma from the 14 patients of a group (cerebral performance category (CPC): 1-2 or CPC: 3-5) were pooled to reach a final volume of 400ÂµL for each group. The two pools were processed conjointly. Total RNA was extracted using miRVana isolation kit (Applied Biosystems), dephosphorylated and labeled using miRNA Complete Labeling and hybridization kit (Agilent). Hybridization was performed on miRNA Human Microarray Release 12.0 slides (Agilent). 4 arrays per pool were hybridized. Scanning was achieved with the Genepix 4000B Scanner (Molecular Devices, Sunnyvale, USA). Raw data were acquired with the Genepix Pro software (Molecular Devices).

2013-01-11 | E-GEOD-34643 | biostudies-arrayexpress

Evaluation of depletion of abundant plasma proteins for proteomics characterization of EVs

Project description:In this study, we aimed to investigate if the removal of abundant plasma proteins prior to EV isolation could improve plasma-derived EV characterization by LC-MS/MS by improving the proteome coverage. Plasma depletion was performed using single-use spin columns prior to SEC-based EV isolation. Afterwards, EVs derived from undepleted and depleted plasma were characterized by mass spectrometry (MS)-based proteomics using a data-independent acquisition (DIA) approach.

2023-07-20 | PXD039240 | Pride

Dendritic cell lineage commitment is instructed by distinct cytokine signals

Project description:Dendritic cells (DC) develop from hematopoietic stem cells, which is guided by instructive signals through cytokines. DC development progresses from multipotent progenitors (MPP) via common DC progenitors (CDP) into DC. Flt3 ligand (Flt3L) signaling via the Flt3/Stat3 pathway is of pivotal importance for DC development under steady state conditions. Additional factors produced during steady state or inflammation, such as TGF-beta1 or GM-CSF, also influence the differentiation potential of MPP and CDP. Here, we studied how gp130, GM-CSF and TGF-beta1 signaling influence DC lineage commitment from MPP to CDP and further into DC. We observed that activation of gp130 signaling promotes expansion of MPP. Additionally, gp130 signaling inhibited Flt3L-driven DC differentiation, but had little effect on GM-CSF-driven DC development. The inflammatory cytokine GM-CSF induces differentiation of MPP into inflammatory DC and blocks steady state DC development. Global transcriptome analysis revealed a GM-CSF-driven gene expression repertoire that primes MPP for differentiation into inflammatory DC. Finally, TGF-beta1 induces expression of DC-lineage affiliated genes in MPP, including Flt3, Irf-4 and Irf-8. Under inflammatory conditions, however, the effect of TGF- beta1 is altered: Flt3 is not upregulated, indicating that an inflammatory environment inhibits steady state DC development. Altogether, our data indicate that distinct cytokine signals produced during steady state or inflammation have a different outcome on DC lineage commitment and differentiation. 6 samples in total. Multipotent progenitor - GM-MPP_1 - GM-MPP_2 Dendritic cell - GM-DC_1 - GM-DC_2 Dendritic cell plus TNFa - GM-TNFa-DC_1 - GM-TNFa-DC_2

2011-11-13 | E-GEOD-29241 | biostudies-arrayexpress

CD71+ HSC/MPP

Project description:CD71+ HSC/MPP

| PRJNA789602 | ENA

Project description:Melanoma and NSCLC-Adeno plasma microbiome

| PRJEB36407 | ENA